CYP24A1 and hypercalcemia disease: Owing to the observational nature of available evidence, limited clinical data, and heterogeneous recommendations, there is no standardized approach to managing hypercalcemia in pregnancy secondary to pathogenic CYP24A1 mutations, and pharmacologic options must take fetal exposure into account.